THE If-CHANNEL INHIBITOR IVABRADINE IN COMBINATION THERAPY FOR PATIENTS WITH STABLE FORMS OF CORONARY HEART DISEASE
- Authors: Durnetsova O.1, Morozova T.1
-
Affiliations:
- First Moscow State Medical University
- Issue: Vol 23, No 7 (2012)
- Pages: 44-48
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115448
- ID: 115448
Cite item
Open Access
Access granted
Abstract
Forty-three patients (27 men and 16 women; mean age 63.24 years) with coronary heart disease (CHD) were examined to assess the clinical and pharmacoeconomic aspects of the use of the If-channel inhibitor ivabradine as part of combination therapy from the data of ECG monitoring, treadmill test, and quality of life (QL) questionnaires. Ivabradine produces anti-ischemic activity, increases the volume and time of fulfilled exercise, reduces heart rate, and improves QL in patients with CHD and stable angina on exertion. The combination therapy using ivabradine is economically more advantageous than the standard therapy without this drug.
Full Text
About the authors
O. Durnetsova
First Moscow State Medical University
T. Morozova
First Moscow State Medical University
Email: temorozova@gmail.com
Professor MD
References
- Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования // Кардиология. - 2005; 10: 45-50.
- Tardif J., Ponikowski P., Kahan T. For the ASSOCIATE study Investigators Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial // Eur. Heart J. - 2009; 30 (5): 540-8.
- Морозова Т.Е., Рыкова С.М., Андрущишина Т.Б. Методы фармакоэкономического анализа лекарственной терапии // М.: Русский врач. - 2009; 40.
Supplementary files
